Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Biovitrum and Santhera sign agreement

Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases

Biovitrum AB, Sweden, and Swiss-based Santhera Pharmaceuticals AG have signed a license and collaboration agreement that grants Biovitrum the exclusive worldwide rights to Santhera´s DPP-IV inhibitor program to select and develop compounds and sell future drugs for a range of metabolic diseases, including type 2 diabetes, obesity and metabolic syndrome.

Under the terms of the agreement, Santhera will receive an upfront payment of Euro 4 million. In addition, this Biotech to Biotech deal allows both parties to receive a significant part of the commercial value of the overall project. Biovitrum and Santhera will share revenues according to a fixed percentage split of future revenues which could include milestones and royalties from sub-licensees. This means Santhera could receive milestone payments which exceed Euro 50 million per marketed product before royalties.

The DPP-IV inhibitor program comprises several distinct chemical series which are protected by a very solid and diverse IP estate. The compounds’ excellent selectivity towards DPP-IV related enzymes, non-covalent binding mode, and attractive pharmacokinetic data results in an overall profile which is highly competitive as compared to other published DPP-IV inhibitors. It is anticipated that the first candidate drug from the DPP-IV program will be selected in Autumn 2005 with Phase I studies starting in 2006.

DPP-IV inhibitors represent one of the most promising new diabetes treatments. They act through enhancing glucose sensitive insulin secretion and insulin sensitivity and, compared to existing treatments, are expected to offer a superior side effect profile in terms of greatly reduced risk of hypoglycemia, weight gain, fluid retention and nausea. DPP-IV inhibitors also offer the convenience of oral dosing. Type 2 diabetes is the most common form, accounting for approximately 90% of all diabetes and affecting some 17 million people in the US alone.

“We are very pleased to collaborate with Santhera on the development of this important new class of oral anti-diabetic drugs, which is generally considered to be among the most promising future treatments for diabetes,” says Mats Pettersson, Chief Executive Officer at Biovitrum.

“Santhera has developed an excellent and innovative medicinal chemistry capability with the diabetes DPP-IV inhibitor project as one of the strongest examples. Santhera´s DPP-IV inhibitors’ excellent safety and therapeutic profile will potentially offer a strong competitive advantage in the marketplace. The signed agreement further consolidates our strength in the metabolic therapeutic area where Biovitrum has significant interests.”

Klaus Schollmeier, Ph.D., Chief Executive Officer of Santhera stated, “Biovitrum is an excellent partner because of its strategic focus on metabolic diseases and specialization in this field. We explored a number of competitive offers for our program and chose to work with Biovitrum as we were impressed by their level of expertise and commitment to developing products quickly and successfully.”

“Out-licensing the DPP-IV program fits perfectly with our corporate strategy to focus our pre-clinical and clinical development as well as commercialization activities in the field of neuromuscular diseases.“

Biovitrum is one of the largest biotechnology companies in Europe, with operations in Stockholm and Uppsala, Sweden and in Cambridge, in the UK. The company combines research and development with commercial operations. The company’s Research & Development operations focus on new pharmaceuticals in primarily obesity and diabetes, inflammation and pain as well as in cancer and eye diseases, while Biovitrum´s Biopharmaceuticals develops and produces protein-based drugs on a contractual basis. Bio

Publisher Contact Information:

Santhera Pharmaceuticals AG
+46-8-697 20 00

Company profile of Santhera Pharmaceuticals AG
Past press releases of Santhera Pharmaceuticals AG.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.